Dov Gertz
Dov Gertz is co-founder and CEO of Converge Bio, which trains generative AI models on the biological languages of DNA, RNA and proteins to help biotech and pharma companies discover drugs faster. The company's experimentally validated systems already support target discovery, antibody design, protein manufacturing optimization and biomarker discovery, and it raised a $25 million Series A in 2026.
Info about the founder
Dov Gertz is co-founder and CEO of Converge Bio, which trains generative AI models on the biological languages of DNA, RNA and proteins to help biotech and pharma companies discover drugs faster. The company's experimentally validated systems already support target discovery, antibody design, protein manufacturing optimization and biomarker discovery, and it raised a $25 million Series A in 2026.